AdCLD CoV19
Alternative Names: AdCLD-CoV19 vaccine - Cellid; AdCLD-CoV19-1; AdCLDCoV19Latest Information Update: 11 Aug 2023
At a glance
- Originator Cellid Company
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 21 Jun 2023 Cellid completes a phase I trial for COVID-19 infections (Prevention) in South Korea (NCT05047692)
- 20 Jun 2023 Cellid in collaboration with International Vaccine Institute terminates a phase II trial in COVID-2019 infections (Prevention, In adults) (IM) based on the sponsor(manufacture)'s decision (NCT05520970)
- 27 Mar 2023 Cellid completes a phase I/II trial in COVID-2019 infections (Prevention) in South Korea (IM, Injection) (NCT04666012)